KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, and Amanda Hodges, director of implementation for ReVital Cancer Rehabilitation, who acts as a bridge between the oncology world and the rehabilitation world, discuss overcoming barriers in practices to help patients with cancer get the rehab care they need, how patients with cancer can benefit from rehab, and defining value.

Related Videos

Related Content

Advertisement

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

July 1st 2025

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

Sabrina McCrear

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 30th 2025

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

Rose McNulty

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

Related Content

Advertisement

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

July 1st 2025

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

Sabrina McCrear

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 30th 2025

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

Rose McNulty

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.